TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7414298

Group type: EXPERIMENTAL
Intervention: Phlebotomized subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypertransfused subjects
Number of subjects: 13

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Controls and hypertransfused subjects only
Number of subjects: 13
Study: 31917372

Group type: EXPERIMENTAL
Intervention: EMPOWER mobile phone app for monitoring well-being and early warning signs (EWSs) of relapse, blended with ongoing peer support.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 120
Study: 31870415

Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program (CHAP) for 1 year
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matched buildings not receiving the CHAP program
Number of subjects: 28
Study: 28107559

Group type: EXPERIMENTAL
Intervention: AVX001 (cPLA2α inhibitor) at 5% dose level
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: AVX001 (combined doses of 3% and 5%)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: AVX001 (any dose)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 25842385

Group type: EXPERIMENTAL
Intervention: Internet-based worksite weight loss intervention
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 1030
Study: 23953069

Group type: EXPERIMENTAL
Intervention: AMH-based algorithm
Number of subjects: 348

Group type: COMPARATOR
Intervention: AFC-based algorithm
Number of subjects: 348
Study: 20961479

Group type: EXPERIMENTAL
Intervention: Haloperidol and Olanzapine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 19342174

Group type: EXPERIMENTAL
Intervention: tricyclic antidepressant medication
Number of subjects: 169

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: (cognitive-behavioral) stress-management therapy plus placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: stress-management therapy plus antidepressant medication
Number of subjects: 169
Study: 19708873

Group type: EXPERIMENTAL
Intervention: Short incubation with ALA plus IPL (30 minutes, n=9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long incubation with ALA plus IPL (3 hours, n=11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IPL alone
Number of subjects: 20
Study: 15869575

Group type: EXPERIMENTAL
Intervention: High-intensity warfarin (INR range 3.0-4.5)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional treatment (warfarin, INR range 2.0-3.0 or aspirin 100 mg/day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High-intensity warfarin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 109
Study: 12473001

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (low-intensity home exercise program)
Number of subjects: 115
Study: 9585282

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Plain bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Number of subjects: 98
Study: 7620002

Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy
Number of subjects: 580

Group type: COMPARATOR
Intervention: Ceftriaxone/tobramycin
Number of subjects: 580
Study: 2696203

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (oral)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Verapamil 1.6 mg (inhalation)
Number of subjects: 107
Study: 324398

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TMP-SMZ
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 90
Study: 11601118

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg daily
Number of subjects: 590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 590
Study: 31077411

Group type: EXPERIMENTAL
Intervention: Protocols with primary outcomes defined
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Protocols with primary outcomes omitted
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Protocols with new primary outcomes introduced
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Protocols with discrepancies in primary outcome time frame
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Protocols with new secondary outcomes introduced
Number of subjects: 49

Group type: COMPARATOR
Intervention: Industry funding
Number of subjects: 49

Group type: COMPARATOR
Intervention: Timing of registration
Number of subjects: 49
Study: 29713153

Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal cannula (HFNC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 27221939

Group type: EXPERIMENTAL
Intervention: Screening for gall bladder cancer in high risk populations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 23982816

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 107

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 107
Study: 22410609

Group type: EXPERIMENTAL
Intervention: Elder health promotion program (health education and exercise) led by a professional leader for 4 weeks, followed by elder health leader and research assistant for 8 weeks (total 12 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 49
Study: 20197789

Group type: EXPERIMENTAL
Intervention: Berry group (diet 1, N=31, 28 completed)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (diet 2, N=30, 22 completed)
Number of subjects: 61
Study: 17694944

Group type: EXPERIMENTAL
Intervention: Dual acid etched and further conditioned with nanometer‐scale crystals of calcium phosphate (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dual acid etched (n = 9)
Number of subjects: 18
Study: 15655140

Group type: EXPERIMENTAL
Intervention: 6% salicylic acid gel plus 0.1% tacrolimus ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6% salicylic acid gel plus vehicle
Number of subjects: 30
Study: 11860410

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment in H. pylori-positive patients (36 patients)
Number of subjects: 66

Group type: COMPARATOR
Intervention: H. pylori-negative/cured patients (43 patients)
Number of subjects: 66
Study: 10439762

Group type: EXPERIMENTAL
Intervention: Piritramid combined with pleural bupivacaine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Piritramid alone
Number of subjects: 37
Study: 7843703

Group type: EXPERIMENTAL
Intervention: Total paracentesis associated with plasma volume expansion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 80
Study: 2297284

Group type: EXPERIMENTAL
Intervention: 600 mg/d cholesterol diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: 200 mg/d cholesterol diet
Number of subjects: 10
Study: 856917

Group type: EXPERIMENTAL
Intervention: H3ChN2Ch virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heq1N2Ch virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31829227

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) testing (i-STAT and complete blood count (CBC), electrocardiograms (ECGs), and x-rays (LODOX®))
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) testing (LODOX®-containing permutations)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Standard ED pathway with traditional diagnostic tests
Number of subjects: 897
Study: 29410545

Group type: EXPERIMENTAL
Intervention: Placental transfusion (DCC or CM)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 461
Study: 26802800

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (6 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 136
Study: 24512061

Group type: EXPERIMENTAL
Intervention: Episodic future thinking (EFT) with positive valence
Number of subjects: 87

Group type: COMPARATOR
Intervention: Episodic future thinking (EFT) with neutral valence
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Positive episodic thinking
Number of subjects: 87
Study: 22876748

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg for three weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for three weeks
Number of subjects: 15
Study: 20712805

Group type: EXPERIMENTAL
Intervention: morphine 0.1 mg.kg⁻¹
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: oxycodone 0.05 mg.kg⁻¹
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: oxycodone 0.1 mg.kg⁻¹
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: oxycodone 0.2 mg.kg⁻¹
Number of subjects: 38

Group type: COMPARATOR
Intervention: saline
Number of subjects: 38
Study: 17534634

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone ointment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15333614

Group type: EXPERIMENTAL
Intervention: Cast immobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation after immobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro force mechanics on skinned human muscle fibers
Number of subjects: 0
Study: 11192337

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral treatment
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Drug treatment with oxybutynin chloride
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo-control condition
Number of subjects: 197
Study: 9625122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: COMPARATOR
Intervention: Alendronate 5 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Alendronate 10 mg/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg q.i.d.
Number of subjects: 79
Study: 7837401

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both sevoflurane and isoflurane anesthesia
Number of subjects: 0
Study: 3166825

Group type: EXPERIMENTAL
Intervention: All program components (lifestyle assessment, physician prescription of lifestyle change, educational materials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parts of the program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No program components
Number of subjects: 0
Study: 31764824

Group type: COMPARATOR
Intervention: MRCP alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined MRI including DWI
Number of subjects: 38
Study: 28527228

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for bilateral quadriceps muscles for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 26392433

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous bone marrow mononuclear cells (BMNC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 23723385

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional physical therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 188
Study: 21700945

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril plus indapamide for eligible patients)
Number of subjects: 4283
Study: 19234590

Group type: EXPERIMENTAL
Intervention: Chocolate Milk (CM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carbohydrate Replacement Drink (CR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fluid Replacement Drink (FR)
Number of subjects: 9
Study: 16605292

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 947
Study: 14682555

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wakefield Depression Inventory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedules for Clinical Assessment in Neuropsychiatry
Number of subjects: 0
Study: 11813774

Group type: EXPERIMENTAL
Intervention: Community-based group health promotion intervention
Number of subjects: 0
Study: 9212380

Group type: EXPERIMENTAL
Intervention: Medical evidence present
Number of subjects: 95

Group type: COMPARATOR
Intervention: Medical evidence absent
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High pain intensity
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Low pain intensity
Number of subjects: 95
Study: 7699376

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-augmented stems (12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-augmented stems (6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonaugmented stems (12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonaugmented stems (6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (Charnley scoring system)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (plain radiographic analysis)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (stereographic evaluation)
Number of subjects: 60
Study: 3451878

Group type: EXPERIMENTAL
Intervention: Alinidine (10 mg i.v. bolus followed by 10 mg h-1 infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30415507

Group type: EXPERIMENTAL
Intervention: Supervised training (counseling and supervised phase for 24 weeks followed by unsupervised training for 24 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unsupervised training (counseling and unsupervised training for 48 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unsupervised training
Number of subjects: 50
Study: 27782950

Group type: EXPERIMENTAL
Intervention: CO2 Laser-assisted Sclerectomy Surgery (CLASS)
Number of subjects: 111
Study: 24402830

Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine (1,250 mg orally QD continuously plus 20 mg/m(2)/day IV)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (1,250 mg orally QD continuously plus 2,000 mg/m(2)/day orally, 2 doses)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Crossover to lapatinib plus vinorelbine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Crossover to lapatinib plus capecitabine
Number of subjects: 112
Study: 23452506

Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 161
Study: 20884421

Group type: EXPERIMENTAL
Intervention: IVUS‐CBA‐BMS
Number of subjects: 521

Group type: COMPARATOR
Intervention: DES (Rapamycin-Eluting Stent)
Number of subjects: 521

Group type: COMPARATOR
Intervention: DES
Number of subjects: 521
Study: 18004635

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 16456382

Group type: EXPERIMENTAL
Intervention: Alpha‐1‐antitrypsin replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed tomography scanning
Number of subjects: 0
Study: 12641014

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated drug-eluting stent
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated drug-eluting stent (NIRx, TAXUS I trial)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated stent (RAVEL and SIRIUS trials)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 266
Study: 9810054

Group type: EXPERIMENTAL
Intervention: Ion-implanted beta-titanium archwires
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unimplanted beta-titanium archwires
Number of subjects: 30
Study: 7704066

Group type: EXPERIMENTAL
Intervention: Pilot orientation program (clinic tour, general information, opportunity to ask questions)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 33
Study: 2576115

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg u.i.d.)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg u.i.d.)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 3
Study: 577889

Group type: EXPERIMENTAL
Intervention: Two-agent therapy (methotrexate and hydrocortisone)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Three-agent therapy (methotrexate, hydrocortisone, and cytosine arabinoside)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Comparison of two-agent and three-agent therapy
Number of subjects: 91
Study: 7044582

Group type: EXPERIMENTAL
Intervention: albendazole 0.4 g (adolescents and adults) or 0.2 g (children)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 186
Study: 31933105

Group type: EXPERIMENTAL
Intervention: QSAR modeling using CORAL software and Monte Carlo method for predicting antioxidant activity
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hybrid model combining hydrogen‐suppressed graph and SMILES descriptors
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Validation of models
Number of subjects: 111
Study: 31029925

Group type: EXPERIMENTAL
Intervention: Organic beet leaves and stalk juice (32 mg EAG/100 mL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Organic beet leaves and stalk juice (77.5 mg EAG/100 mL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study: 29322254

Group type: EXPERIMENTAL
Intervention: Thermal mineral water treatment for 3 weeks (15 occasions) on top of usual musculoskeletal pain killer treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional musculoskeletal pain killer treatment
Number of subjects: 105
Study: 27028128

Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Opt-out plus
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Opt-out
Number of subjects: 1319
Study: 25079040

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt with low-calorie diet (PLCD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Regular yogurt with low-calorie diet (RLCD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt without low-calorie diet (PWLCD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (Regular yogurt with low-calorie diet)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (Probiotic yogurt without low-calorie diet)
Number of subjects: 75
Study: 21636614

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 460
Study: 18436468

Group type: EXPERIMENTAL
Intervention: Physiotherapy with emphasis on selectively retraining the VMO (Selective)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Physiotherapy with emphasis on general strengthening of the quadriceps femoris muscles (General)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No-treatment control group (Control)
Number of subjects: 69
Study: 17909379

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials (CRTs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Recommendations for increasing acceptability of CRTs
Number of subjects: 34
Study: 15546141

Group type: EXPERIMENTAL
Intervention: Bibliotherapy alone (BT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bibliotherapy plus phone contact (BT+PC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phone contact alone (PC)
Number of subjects: 0
Study: 11986125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study: 9661571

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg atracurium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg vecuronium
Number of subjects: 30
Study: 7661384

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 33

Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 33
Study: 2674875

Group type: EXPERIMENTAL
Intervention: Ceftazidime + amikacin (CA)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Ceftazidime + pefloxacin (CP)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Ceftazidime + pefloxacin (CP) and Ceftazidime + amikacin (CA)
Number of subjects: 352
Study: 1253157

Group type: EXPERIMENTAL
Intervention: Transfer factor immunotherapy
Number of subjects: 1
Study: 30966802

Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy and IMRT
Number of subjects: 20
Study: 29130724

Group type: EXPERIMENTAL
Intervention: Probiotics therapy for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26083697

Group type: EXPERIMENTAL
Intervention: Recreational alpine skiing intervention (2-3 times per week for 12 weeks, totaling 25.5 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recreational alpine skiing intervention
Number of subjects: 16
Study: 24351693

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: MTA Angelus
Number of subjects: 139

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 139
Study: 21923988

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS) given every 14 days until 33+6 weeks or birth
Number of subjects: 1858

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1858

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS)
Number of subjects: 1858